Stock Track | Summit Therapeutics Soars 5.03% in After-Hours on Positive Lung Cancer Drug Trial Results

Stock Track06-02

Summit Therapeutics PLC (SMMT) experienced a significant after-hours surge of 5.03%, following a day of volatile trading activity driven by mixed reactions to new clinical trial data for its lung cancer drug candidate, ivonescimab.

The biopharmaceutical company presented positive Phase 3 results from the HARMONi-6 trial, showing that ivonescimab, developed with partner Akeso, helped patients with advanced squamous non-small cell lung cancer live an average of 27.9 months. This represented a 15% higher survival rate and a 34% reduction in the risk of death compared to an existing immunotherapy treatment combined with chemotherapy.

Initial pre-market gains were reversed during the intraday session as analysts raised concerns about the drug's efficacy in patients aged 65 and above and the translatability of the China-only trial data to global populations. However, the after-hours rally suggests renewed investor optimism, focusing on the drug's potential to become a first-line treatment that outperforms current standards in a challenging cancer setting.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153625275?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 05:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153625275","market":"us","top_or_hot":-1,"title":"Stock Track | Summit Therapeutics Soars 5.03% in After-Hours on Positive Lung Cancer Drug Trial Results","media":"Stock Track","content":"<p>Summit Therapeutics PLC (SMMT) experienced a significant after-hours surge of 5.03%, following a day of volatile trading activity driven by mixed reactions to new clinical trial data for its lung cancer drug candidate, ivonescimab.</p><p>The biopharmaceutical company presented positive Phase 3 results from the HARMONi-6 trial, showing that ivonescimab, developed with partner Akeso, helped patients with advanced squamous non-small cell lung cancer live an average of 27.9 months. This represented a 15% higher survival rate and a 34% reduction in the risk of death compared to an existing immunotherapy treatment combined with chemotherapy.</p><p>Initial pre-market gains were reversed during the intraday session as analysts raised concerns about the drug's efficacy in patients aged 65 and above and the translatability of the China-only trial data to global populations. However, the after-hours rally suggests renewed investor optimism, focusing on the drug's potential to become a first-line treatment that outperforms current standards in a challenging cancer setting.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Summit Therapeutics Soars 5.03% in After-Hours on Positive Lung Cancer Drug Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Summit Therapeutics Soars 5.03% in After-Hours on Positive Lung Cancer Drug Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-02 05:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Summit Therapeutics PLC (SMMT) experienced a significant after-hours surge of 5.03%, following a day of volatile trading activity driven by mixed reactions to new clinical trial data for its lung cancer drug candidate, ivonescimab.</p><p>The biopharmaceutical company presented positive Phase 3 results from the HARMONi-6 trial, showing that ivonescimab, developed with partner Akeso, helped patients with advanced squamous non-small cell lung cancer live an average of 27.9 months. This represented a 15% higher survival rate and a 34% reduction in the risk of death compared to an existing immunotherapy treatment combined with chemotherapy.</p><p>Initial pre-market gains were reversed during the intraday session as analysts raised concerns about the drug's efficacy in patients aged 65 and above and the translatability of the China-only trial data to global populations. However, the after-hours rally suggests renewed investor optimism, focusing on the drug's potential to become a first-line treatment that outperforms current standards in a challenging cancer setting.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMMT","symbol_name":"Summit Therapeutics PLC","start_time":0,"source_url":"","article_id":"1153625275","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153625275","pubTimestamp":1780350642,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Summit Therapeutics PLC (SMMT) experienced a significant after-hours surge of 5.03%, following a day of volatile trading activity driven by mixed reactions to new clinical trial data for its lung...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMMT":"Summit Therapeutics PLC"},"translate_title":"个股追踪|肺癌药物试验结果积极Summit Therapeutics盘后大涨5.03%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":1},"content_text":"Summit Therapeutics PLC (SMMT) experienced a significant after-hours surge of 5.03%, following a day of volatile trading activity driven by mixed reactions to new clinical trial data for its lung cancer drug candidate, ivonescimab.The biopharmaceutical company presented positive Phase 3 results from the HARMONi-6 trial, showing that ivonescimab, developed with partner Akeso, helped patients with advanced squamous non-small cell lung cancer live an average of 27.9 months. This represented a 15% higher survival rate and a 34% reduction in the risk of death compared to an existing immunotherapy treatment combined with chemotherapy.Initial pre-market gains were reversed during the intraday session as analysts raised concerns about the drug's efficacy in patients aged 65 and above and the translatability of the China-only trial data to global populations. However, the after-hours rally suggests renewed investor optimism, focusing on the drug's potential to become a first-line treatment that outperforms current standards in a challenging cancer setting.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153625275","isCrawlerRequest":true}